Adverse reactions to cortrimoxazole in HIV-infected patients: Predictive factors an subsequent HIV disease progression

Scandinavian Journal of Infectious Diseases

Volumn 33, Issue 10, 2001, Pages 759-764

  Rabaud, C ^a   Charreau, I ^b   Izard, S ^b   Raffi, F ^c   Meiffredy, V ^b   Leport, C ^d   Guillemin, F ^a   Yeni, P ^d   Aboulker, J P ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; ANTIINFECTIVE AGENT;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FEVER; FRANCE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PREDICTION; RASH; SURVIVAL; TOXOPLASMOSIS; ANALYSIS OF VARIANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; MORTALITY; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; MALE; PNEUMONIA, PNEUMOCYSTIS; SURVIVAL RATE; TOXOPLASMOSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0034740186     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655401317074581     Document Type: Article

References (30)

1. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection
2. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis against Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
3. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: A prospective, randomized, controlled clinical study
4. Update on consensual proposals (1993 February). Role of cotrimoxazole in the primary prevention of toxoplasmosis in patients with HIV infection
5. Toxoplasmic encephalitis in HIV-infected persons: Risk factors and trend
6. Cotrimoxazole is effective as primary prophylaxis for toxoplasmic encephalitis in HIV-infected patients: A case control study
7. Toxoplasma gondii infection in advanced HIV infection
8. A meta-analysis of the relative efficacy of Pneumocystis carinii prophylactic regimens
9. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: A two-year Italian multicentric randomized controlled trial
10. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and Toxoplasma encephalitis in HIV-infected patients
11. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus
12. Sulfamethoxazole is metabolized to the hydroxylamine in humans
13. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients
14. Toxicity of sulfonamide-reactive metabolites in HIV-infected, and noninfected cells
15. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: Allergic or toxic?
16. Toxoplasmose cérébrale chez les patients infectés par le VIH intolérants au cotrimoxazole
17. Intention-to-treat vs. on-treatment analyses of clinical trial data: Experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients
18. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
19. Revision of the case definition of acquired immune deficiency syndrome
20. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
21. Regression models and life tables
22. Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: Lack of hematologic toxicity and relationship of side effects to CD4+ lymphocyte count
23. Cutaneous adverse reactions and CD4+ cell counts in human immunodeficiency virus-infected patients receiving Trimethoprim-sulfamethoxazole
24. Rapid disease progression in human imunodeficiency virus type1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis
25. N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients
26. Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash
27. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya
28. Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation
29. Toxidermies au cours de l'infection à VIH
30. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis